IDEAYA: (Melanoma with GNAQ/11 Mutations or PRKC Fusions) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called IDE196 (the study drug) is a safe and effective treatment for uveal melanoma (melanoma in the eye) that has spread to another part of the body or other types of cancer with a tumor mutation in genes called GNAQ, GNA11, or PRKC.
Uveal Melanoma & Other Cancers with Gene Mutations
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with uveal melanoma that has spread to other parts of their body (metastasis); OR
- Are diagnosed with another form of cancer that has a tumor mutation associated with the genes GNAQ, GNA11, or PRKC
For more information about who can be in this study, please contact the study team at carolann.wiggs@duke.edu.
What is Involved?
If you choose to join the study, you will come in for a screening visit to see if you are eligible. During this visit, you will:
- Have a physical exam
- Have blood draws and give urine samples
- Have an eye exam
- Get a chest X-ray
- Have lung function tests
- If applicable, have a tumor biopsy to test for mutations in its genes
If you are eligible, you will continue on to the dosing period. During this period, you will:
- Take the study drug along with another drug called crizotinib by mouth every day for drug cycles that last 4 weeks each
- Have images (CT or MRI) taken of your tumors every 2 months for up to a year
The number of drug cycles you do will depend on how your body and cancer respond to the study drug and crizotinib.
Study Details
